Sunday, November 8, 2026

GBP/EUR Bearish Momentum With A 1% Slide In The Last 21 Sessions

ViaNews Editorial Team

November 9, 2023

GBP/EUR Bearish Momentum With A 1% Slide In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.55% for the last 21 sessions. At 15:08 EST on Thursday, 9 November, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 3.071% up from its 52-week low and 2.489% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.03%, a negative 0.01%, and a positive 0.21%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.23% (last week), 0.17% (last month), and 0.21% (last quarter), respectively.

News about

  • Eur/usd consolidates in a range above 1.0700, remains close to multi-week top set on Monday. According to FXStreet on Tuesday, 7 November, "The EUR/USD pair extends its sideways consolidative price move during the Asian session on Tuesday and trades below its highest level since September 13 touched the previous day. ", "The USD Index (DXY), which tracks the Greenback against a basket of currencies, builds on the overnight bounce from a near eight-week low and turns out to be a key factor acting as a headwind for the EUR/USD pair. "
  • Eur/usd: 1.0650 seems the risk today – ING. According to FXStreet on Tuesday, 7 November, "The Euro story looks weak and EUR/USD will only rally if the US story is weak enough to trigger some clear bullish flattening of the US yield curve. "
  • According to DailyForex on Tuesday, 7 November, "It is noteworthy that the current juncture positions the market at the apex of a bearish flag formation, a pattern that closely mirrors the configuration observed in the EUR/USD currency pair."
  • Eur/usd forex signal: forecast as the bullish charge stalls - 07 November 2023. According to DailyForex on Tuesday, 7 November, "The EUR/USD pair has risen after the latest European Central Bank (ECB) and the Federal Reserve decisions. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bullish viewBuy the EUR/USD pair and set a take-profit at 1.0810."
  • Eur/usd technical analysis: upward trend awaits further stimulus - 07 November 2023. According to DailyForex on Tuesday, 7 November, "According to the performance on the daily chart below, the price of the EUR/USD is in the stage of breaking the general downward trend, and stability above the 1.0800 resistance will be important for more bulls' control over the trend. ", "On the other hand, over the same period, bullish hopes for the EUR/USD pair may evaporate if it moves towards the 1.0620 support level again."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com